CD274 and non-small cell lung carcinoma: In contrast, in a study conducted in patients with NSCLC with a high PD-L1 expression level (tumor proportion score ≥ 50%) treated with pembrolizumab monotherapy vs chemotherapy, the single-agent ICB provided both PFS and OS benefit over chemotherapy (Reck et al. 2016).